Deiodinase Selenocysteine Active Sites, Th1/Th17 Immune Balance Modulation by VDR, and GPx4 Protection of Thyroid Follicular Cells in Hashimoto's Thyroiditis

[Image: Deiodinase enzyme active site structure: T4 substrate → selenocysteine (Sec) nucleophilic attack at C5' iodine → selenenyl-iodide intermediate → T3 product release, with selenium insufficiency → DIO2 activity decline → elevated rT3 pathway labeled]

The iodothyronine deiodinase family (DIO1, DIO2, DIO3) catalyzes the deiodination reactions that interconvert thyroid hormone forms. DIO1 (type 1 deiodinase) and DIO2 (type 2) catalyze outer ring deiodination converting prohormone T4 (thyroxine) to the metabolically active T3 (triiodothyronine) by removing the 5'-iodine from T4's outer phenolic ring. DIO1 is expressed primarily in liver and kidney; DIO2 is expressed in brain, pituitary, thyroid, heart, and adipose tissue — and is the dominant source of local T3 in most tissues, making it clinically more critical than DIO1 for intracellular thyroid hormone action.

The catalytic mechanism of both DIO1 and DIO2 depends absolutely on selenocysteine (Sec, encoded by UGA selenocysteine codon) at the active site. Unlike cysteine (the standard sulfur-containing homolog), selenocysteine has a pKa of approximately 5.4 vs cysteine's 8.3, meaning selenocysteine is fully ionized and nucleophilically active at physiological pH. This enhanced nucleophilicity enables the thiol-disulfide exchange reaction that removes iodine from the T4 phenolic ring via a selenenyl-iodide intermediate — a reaction that is essentially impossible with a cysteine active site at physiological conditions. In selenium deficiency, DIO2 activity declines before DIO1 due to DIO2's lower selenocysteine turnover rate and its dependence on selenium reincorporation via SECISBP2 (selenocysteine insertion sequence-binding protein 2). Clinical consequence: even moderate selenium insufficiency (serum Se below 85 μg/L) reduces T4→T3 conversion efficiency, producing elevated rT3 (reverse T3, generated by DIO3 outer ring deiodination as an alternative pathway) and low free T3 — contributing to hypothyroid symptoms despite adequate T4 levels.

[Image: Thyroid follicular cell H2O2 cycle: DUOX2 → H2O2 generation for TPO iodination → GPx4 (selenium/GSH-dependent) H2O2 neutralization, with selenium deficiency → inadequate GPx4 → oxidative Tg/TPO modification → neo-antigen APC presentation → autoantibody amplification loop]

Normal thyroid hormone synthesis requires high local concentrations of H2O2 within thyroid follicular cells. DUOX2 (dual oxidase 2) generates H2O2 at the apical membrane of follicular cells to oxidize iodide (I-) to iodine (I0) — the reactive form used by thyroid peroxidase (TPO) to iodinate tyrosine residues on thyroglobulin. This H2O2 generation is essential for thyroid hormone biosynthesis but creates an inherently oxidative intracellular environment. The thyroid gland contains the highest selenium concentration per gram of any organ in the body — a distribution that reflects the extraordinary antioxidant demand of this H2O2-rich environment.

Glutathione peroxidase 4 (GPx4, PHGPx — phospholipid hydroperoxide glutathione peroxidase) is the selenium-dependent enzyme responsible for neutralizing H2O2 and lipid hydroperoxides within thyroid follicular cells. GPx4's active site selenocysteine reduces H2O2 to H2O and organic hydroperoxides to their corresponding alcohols, using glutathione (GSH) as the electron donor. In selenium-insufficient thyroid tissue, GPx4 activity is inadequate to neutralize the H2O2 generated by normal DUOX2-mediated iodide oxidation — leading to oxidative damage of thyroglobulin and TPO proteins, protein carbonylation, and neo-antigen generation. These oxidatively modified thyroid proteins may be presented by antigen-presenting cells (APCs) as foreign antigens, amplifying the autoimmune response. Selenium supplementation (200μg/day as selenomethionine or sodium selenite) maintains GPx4 activity, reduces TPOAb titers in multiple RCTs (mean reduction 35–40% over 12 months), and reduces sonographic heterogeneity on thyroid ultrasound — consistent with reduced inflammatory infiltration.

[Image: Th1/Th17 vs Treg balance in Hashimoto's: Th1 (IFN-γ, T-bet) + Th17 (IL-17) driving thyroid infiltration, vs Treg (FoxP3) peripheral tolerance; VDR/calcitriol suppression of T-bet/NF-κB + FoxP3 upregulation labeled, with low 25(OH)D → impaired Treg generation → elevated TPOAb correlation indicated]

Hashimoto's thyroiditis is immunologically characterized by Th1-dominant cellular immunity (CD8+ cytotoxic T cell infiltration, IFN-γ, TNF-α production) and Th17 contribution (IL-17, IL-21-mediated amplification of autoantibody production and tissue damage), with deficient Treg (regulatory T cell) suppressive function failing to maintain peripheral tolerance to thyroid antigens. The Th1/Treg balance is directly modulated by vitamin D receptor signaling: 1,25(OH)2D (calcitriol) binding to VDR in naïve CD4+ T cells suppresses Th1 differentiation by reducing T-bet and IFN-γ transcription through VDRE-mediated interference with NF-κB and AP-1 binding. Simultaneously, VDR activation promotes FoxP3 expression in Treg precursors — FoxP3 being the master transcription factor for Treg lineage commitment and suppressive function.

The clinical VDR-Hashimoto's connection is supported by multiple convergent data streams: (1) VDR polymorphisms (Fok1, BsmI, TaqI variants) are significantly over-represented in Hashimoto's patients vs. controls in meta-analyses; (2) low 25(OH)D levels correlate with elevated TPOAb titers in cross-sectional and prospective studies (each 10 ng/mL decrease in 25(OH)D associated with approximately 15–25% TPOAb titer increase); (3) vitamin D supplementation RCTs in Hashimoto's show TPOAb titer reductions of 20–30% at 6 months with doses achieving 25(OH)D ≥40 ng/mL. The VDR-Treg mechanism provides a mechanistic explanation for these clinical observations: calcitriol-driven FoxP3 Treg generation creates population-level Treg suppressive capacity that constrains effector T cell access to thyroid tissue.

[Image: Iodine-thyroglobulin immunogenicity mechanism: excess iodide → DUOX2 H2O2 surge + highly iodinated Tg (HIT-Tg) formation → APC presentation → T cell activation → TPOAb/TgAb amplification, with normal vs excess iodine comparison and safe urinary iodine range labeled]

Epidemiological data from populations transitioning from iodine deficiency to sufficiency — and from Western populations consuming iodine-fortified diets — consistently show increased Hashimoto's prevalence with increasing iodine intake above sufficiency thresholds. The Wolff-Chaikoff effect (autoregulatory TSH-independent iodide organification inhibition at supraphysiological iodide concentrations) represents the acute thyroid protective response to excess iodide. Chronically, the mechanism of iodine-driven autoimmunity operates through two pathways.

First, increased iodination of thyroglobulin creates highly iodinated thyroglobulin (HIT-Tg) forms — with 26–30 iodinated tyrosine residues vs the 4–8 residues in physiologically adequate conditions. HIT-Tg is a more potent T cell antigen: the iodinated epitopes are recognized by thyroid-specific CD4+ and CD8+ T cells, and iodine-dense thyroglobulin has 5–10× higher immunogenic potency in NOD.H-2h4 mouse models. Second, high iodide loads transiently exceed thyroid NIS (sodium-iodide symporter) capacity, increasing intracellular free iodide available for DUOX2-mediated H2O2 generation — amplifying oxidative stress and GPx4 demand in a feed-forward cycle. The clinical recommendation for Hashimoto's patients is iodine sufficiency without excess: target urinary iodine 150–250 μg/day (vs the population median of 150 μg/day), avoiding kelp, high-dose iodine supplements, and iodine-containing medications (amiodarone, povidone-iodine frequent use) that can deliver gram-level iodide loads acutely.